NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Analysis

60 Degrees Pharmaceuticals, Inc. (SXTP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SXTP

$0.92

−$0.01 (−1.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SXTP with… →

SXTP Key Statistics

As of Sep 4, 2026
Trading
Open
$0.93
Previous Close
$0.93
Day's Range
0.90–0.99
52-Week Range
0.90–8.62
Volume
57.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.54
Valuation
Market Cap
$3.23M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.64
Financials (FY)
Revenue (FY)
$1.01M+65.49%
Net Income (FY)
−$7.37M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.52M
1-Year Return
−84.48%
Dividend and dates
Avg Volume
107.32K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SXTP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.77%
2025−92.12%
2024−89.46%
2023 (partial year)−78.21%

As of September 4, 2026.

SXTP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.01M−$7.37M−732.5%
2024$607.57K−$7.95M−1308.0%
2023$253.57K−$3.77M−1485.1%
2022$223.21K−$6.18M−2769.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.01M$223.78K−$7.76M−$7.37M−732.5%
2024$607.57K$222.81K−$9.72M−$7.95M−1308.0%
2023$253.57K−$220.98K−$5.15M−$3.77M−1485.1%
2022$223.21K−$209.16K−$1.75M−$6.18M−2769.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SXTP Valuation vs Biotechnology Median

Median of 656 stocks
MetricSXTPBiotechnology medianvs median
P/S ratio2.6615.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

60 Degrees Pharmaceuticals, Inc. (SXTP) carries a market capitalisation of $3.23M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 3 employees.

The 52-week range on file runs from $0.90 to $8.62. SXTP last closed at $0.92 on September 4, 2026. That is −$0.01 (−1.18%) against the previous close. The latest close sits 2.46% above that 52-week low.

Financial Health

In fiscal 2025, 60 Degrees Pharmaceuticals, Inc. reported revenue of $1.01M. That is +65.49% against the prior fiscal year, when revenue was $607.57K. The same year closed with a net loss of $7.37M. The reported profit margin is 0%. Trailing earnings per share are −2.64.

Across the 4 fiscal years on file, revenue moves from $223.21K in 2022 to $1.01M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.66. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −84.48%. Measured over 3 years, that is −86.04% a year compounded. The reported beta is 2.54. Annualized volatility over the trailing 3 years is 160.62%.

Growth & Income

The record shows no dividend for SXTP.

Across the complete calendar years on file, 2024 returned −89.46% and 2025 returned −92.12%. 2026 is still running; the price is −54.77% year to date.

Peer Comparison

60 Degrees Pharmaceuticals, Inc. (SXTP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
60 Degrees Pharmaceuticals, Inc. SXTP $3.23M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. 60 Degrees Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Visit website →